Coherus Oncology (CHRS) Retained Earnings (2013 - 2026)
Coherus Oncology (CHRS) posted Retained Earnings of $1.5 billion for Q1 2026, up 3.88% sequentially from $1.4 billion in Q4 2025, and up 5.32% YoY from $1.4 billion in Q1 2025.
Coherus Oncology (CHRS) Retained Earnings (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Retained Earnings for 14 years, with the latest figure at $1.5 billion in Q1 2026.
- Quarterly Retained Earnings rose 5.32% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 5.32% YoY) and the FY2025 annual result came in at $1.4 billion, up 525251.27% from the prior year.
- Retained Earnings advanced to $1.5 billion in Q1 2026 per CHRS's latest filing, from $1.4 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.5 billion in Q1 2026 and troughed at -$1.5 billion in Q2 2023.
- A 5-year average of $93.8 million and a median of -$272000.0 in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings tumbled 540717.04% in 2023, then jumped 525251.27% in 2025.
- Over 5 years, Retained Earnings stood at -$1.3 billion in 2022, then soared by 203.33% to $1.4 billion in 2023, then plunged by 100.02% to -$275000.0 in 2024, then surged by 525251.27% to $1.4 billion in 2025, then grew by 3.88% to $1.5 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $1.5 billion, $1.4 billion, and -$1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | 1.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Bn |
| Mar 31, 2026 | 1.50 Bn |
| Dec 31, 2025 | 1.44 Bn |
| Sep 30, 2025 | -1.35 Bn |
| Jun 30, 2025 | -275,000.00 |
| Mar 31, 2025 | 1.42 Bn |
| Dec 31, 2024 | -275,000.00 |
| Sep 30, 2024 | -275,000.00 |
| Jun 30, 2024 | 1.41 Bn |
| Mar 31, 2024 | -272,000.00 |
| Dec 31, 2023 | 1.39 Bn |
| Sep 30, 2023 | -265,000.00 |
| Jun 30, 2023 | -1.46 Bn |
| Mar 31, 2023 | -1.42 Bn |
| Dec 31, 2022 | -1.34 Bn |
| Sep 30, 2022 | -270,000.00 |
| Jun 30, 2022 | -270,000.00 |
| Mar 31, 2022 | -272,000.00 |
| Dec 31, 2021 | -270,000.00 |
| Sep 30, 2021 | 1.14 Bn |